Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Eustace

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Oncogene|February 12, 2020
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancerSean P Kennedy, Michael O'Neill, Darren Cunningham, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancersMalgorzata Milewska, Mattia Cremona, Clare Morgan, et al.
Cancers|April 20, 2019
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer CellsPatricia Gaule, Nupur Mukherjee, Brendan Corkery, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
Research in Social & Administrative Pharmacy : RSAP|July 10, 2025
Pharmacist prescribing in cancer services: a scoping reviewL Johnson, S Khattab, J Strawbridge, et al.
Nanoscale|March 11, 2025
Synthesis of carbon dots from spent coffee grounds: transforming waste into potential biomedical toolsYingru Zhou, Adalberto Camisasca, Sofia Dominguez-Gil, et al.
Oncology Letters|April 30, 2017
MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell linesTimothy D Rohrbach, Robert B Jones, Patricia H Hicks, et al.
Oncotarget|November 22, 2017
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinibJohn O'Shea, Mattia Cremona, Clare Morgan, et al.
British Journal of Cancer|September 17, 2009
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cellsD L Roberts, K J Williams, R L Cowen, et al.
British Journal of Cancer|March 18, 2010
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisN Walsh, S Kennedy, A M Larkin, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Oncogene|February 12, 2020
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancerSean P Kennedy, Michael O'Neill, Darren Cunningham, et al.
Therapeutic Advances in Medical Oncology|February 1, 2018
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancersMalgorzata Milewska, Mattia Cremona, Clare Morgan, et al.
Cancers|April 20, 2019
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer CellsPatricia Gaule, Nupur Mukherjee, Brendan Corkery, et al.
Investigational New Drugs|April 23, 2020
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd ALaura Breen, Patricia B Gaule, Alexandra Canonici, et al.
Research in Social & Administrative Pharmacy : RSAP|July 10, 2025
Pharmacist prescribing in cancer services: a scoping reviewL Johnson, S Khattab, J Strawbridge, et al.
Nanoscale|March 11, 2025
Synthesis of carbon dots from spent coffee grounds: transforming waste into potential biomedical toolsYingru Zhou, Adalberto Camisasca, Sofia Dominguez-Gil, et al.
Oncology Letters|April 30, 2017
MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell linesTimothy D Rohrbach, Robert B Jones, Patricia H Hicks, et al.
Oncotarget|November 22, 2017
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinibJohn O'Shea, Mattia Cremona, Clare Morgan, et al.
British Journal of Cancer|September 17, 2009
Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cellsD L Roberts, K J Williams, R L Cowen, et al.
British Journal of Cancer|March 18, 2010
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisN Walsh, S Kennedy, A M Larkin, et al.
Pageof 13